SB 815 - This act prohibits health benefit plans from imposing cost-sharing, as defined in the act, on an enrollee in excess of $30 per 30-day supply of a prescription insulin drug.

The act applies to health benefit plans delivered, issued, continued, or renewed in the state on or after January 1, 2023.

This act is substantially similar to SB 264 (2021), and similar to SB 914 (2020), HB 1649 (2020), provisions in HB 2682 (2020), provisions in HB 1987 (2020), and provisions in HB 2163 (2020).


Return to Main Bill Page